Rallybio Corporation Common Stock
RLYBRallybio Corporation (RLYB) is a biotechnology company focused on developing and commercializing targeted therapies for serious genetic and rare diseases. The company primarily invests in innovative treatments aimed at addressing unmet medical needs through novel biologics and gene therapies.
Company News
Monteverde & Associates PC, a recognized class action securities firm, is investigating four major M&A transactions: Calisa Acquisition Corp.'s merger with Goodvision AI Inc., Talkspace Inc.'s sale to Universal Health Services Inc. at $5.25 per share, Jet.AI Inc.'s merger with flyExclusive Inc., and Rallybio Corporation's merger with Candid Thera...
Rallybio Corporation announced a merger agreement with Candid Therapeutics Inc., which has secured over $505 million in financing. The combined company will have approximately $700 million in pro-forma cash to support operations through 2030 and advance T-cell engager therapeutics for autoimmune diseases. Rallybio shares surged 29.05% to $9.73, r...
Recursion Pharmaceuticals acquired full ownership of REV102, an ENPP1 inhibitor program for treating hypophosphatasia, from Rallybio, reducing pipeline uncertainty and potentially adding value to its drug development efforts.
Rallybio Corporation sold its interest in REV102, a preclinical ENPP1 inhibitor for hypophosphatasia, to Recursion Pharmaceuticals for up to $25 million, extending its cash runway into mid-2027.
Shares of JPMorgan Chase & Co. (NYSE: JPM) fell sharply during Friday’s session following first-quarter earnings. Net revenue (managed) of $42.5 billion (+8% Y/Y), beating the consensus of $41.8 billion. Excluding an item resulted in an increase of $550 million (after tax) to reported net income from $13.4 billion to $14.0 billion and an incre...
